1101 GMT - AstraZeneca's China troubles seem manageable, Quilter Cheviot healthcare analyst Sheena Berry says in a note. The British pharma company facing potential charges from an import tax allegation against some of its employees in China creates a slight overhang but entails an amount that it can handle, the analyst says. "China has proven to be an overhang on the stock following the fraud investigations of several individuals, and questions remain on exactly what impact this might have on operations in China," she says. Shares are up 5.2% at 117.02 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 06:02 ET (11:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.